Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody TST003 takes on Hard-to-Treat cancers

NCT ID NCT05731271

Ongoing Disease control Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called TST003 in about 111 people with advanced solid tumors (cancers that have spread or cannot be removed by surgery). TST003 is an antibody that blocks a protein called GREM1, which may help tumors grow. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors. Participants receive the drug through an IV once every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TST003 (a lab-made antibody that targets a protein called GREM1)
What this could lead to
If it works, this could lead to a new treatment option for people with certain advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 111 participants, so the drug may not prove effective or may have unexpected side effects. It is also only for patients with tumors that have a specific marker (GREM1 positive).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL ADENOCARCINOMA LOCALLY ADVANCED SOLID TUMOR METASTATIC TUMOR

Contacts and locations

Locations

  • Mary Crowley

    Dallas, Texas, 75231, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • OHSU

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.